drug
nusinersen
Marketedupdated 3mo agoby $BIIB BIOGEN INC.
Approvedannual revenue · 2024–2024peak $1.6B
community read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying nusinersen
- —Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)
- phase2A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
- phase1A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
- phase3A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
- phase2A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
- phase4A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)
- phase3Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
- —Adult SMA Research and Clinical Hub
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 11, 2027
330 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Mar 4, 2036method-of-use (U-2094)US 12013403
- Sep 11, 2035method-of-use (U-1942)US 10436802
- Jan 9, 2034method-of-use (U-1943)US 9926559
- Dec 23, 2030compositionUS 83619774.4y
- Nov 24, 2030method-of-use (U-1941)US 89808534.3y
- Jun 17, 2030method-of-use (U-1943)US 97177503.8y
- Jul 11, 2027compositionUS 7838657330d
News(3)
- Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?Three years after Qalsody was approved by the FDA as the first drug to target a genetic cause of ALS, some patients are reporting not only disease stabilization but also improvement of symptoms.biospace · 4d ago
- Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology pushBetter-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.biopharma_dive · 16d ago
- ‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a whileBiogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.fiercebiotech · 16d ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that